title: Sorafenib regulating ERK signals pathway in gastric cancer cell.
abstract: The involvement of ERK signals in gastric carcinoma was investigated using Western blot, MTT, and flow cytometric analysis in cultured cells SGC7901. Results showed that treatment of sorafenib potently inhibited gastric SGC7901 cells proliferation, migration, invasion as well as promoted apoptosis. Treatment of sorafenib significantly decreased phosphorylation activation of ERK protein in a dose-dependent manner. Treatment of sorafenib still significantly increased caspase-3, bax, cyt-c protein expression and decreased bcl-2 protein in a dose-dependent manner. Our study confirms that ERK signals pathway is closely associated with development of gastric cancer. Deactivation of phosphorylation of ERK protein is one of the mechanisms of sorafenib inhibiting gastric cancer.
authors.affiliation: Department of Plastic Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China.
authors.forename: Liu Wei
authors.initials: LW
authors.lastname: Juan
authors.affiliation: Department of Urology, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China.
authors.forename: Lin Ming
authors.initials: LM
authors.lastname: En
authors.affiliation: Department of Urology, The First Affiliated Hospital, Sun Yat-sen University, PR China.
authors.forename: Lin
authors.initials: L
authors.lastname: Hao
authors.affiliation: Department of Urology, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China.
authors.forename: Hong Ying
authors.initials: HY
authors.lastname: Kai
authors.affiliation: Department of Gynaecology, The First Affiliated Hospital of Shantou University Medical College, Shantou, PR China. Electronic address: jhuang8947@126.com.
authors.forename: Huang
authors.initials: H
authors.lastname: Ju
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects*; D046931:Microcystis / Q000378:metabolism*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D000077157:Sorafenib; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib
keywords: Cell cycle; ERK signal pathway; Gastric cancer; SGC7901